Semaglutide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Semaglutide: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome
One-Sentence Summary
Semaglutide is a GLP-1 receptor agonist originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for focal stiff limb syndrome, but this is a graph-based prediction only, with 0 clinical trials and 0 publications currently supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Type 2 diabetes mellitus (the registration records compiled for this report contain no approved indication text) |
| Predicted New Indication | Focal stiff limb syndrome |
| TxGNN Prediction Score | 98.64% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 15 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, semaglutide is a GLP-1 receptor agonist that supports glycaemic control and appetite regulation. Its efficacy in type 2 diabetes is established.
No mechanistic link to focal stiff limb syndrome has been established. This is a rare autoimmune/neurological disorder within the stiff-person spectrum, linked to GABAergic and anti-GAD-related dysfunction. GLP-1 receptor agonism has no known role in this pathophysiology. Any anti-inflammatory or neuromodulatory effect is speculative.
The high score probably reflects graph associations, such as the overlap between anti-GAD autoimmunity and autoimmune diabetes. The same score (98.64%) was given to classic stiff person syndrome, which suggests a shared graph neighbourhood rather than disease-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for focal stiff limb syndrome.
The literature retrieved for the lower-ranked prediction, pancreatic agenesis, is preclinical or safety-focused and shows no benefit in that disease.
Other Predicted Indications (Ranks 2–10)
All other predictions are also Evidence Level L5 with a Hold recommendation, and none has clinical trial support.
| Rank | Predicted Indication | Score | Assessment |
|---|---|---|---|
| 2 | Classic stiff person syndrome | 98.64% | Indirect and speculative; anti-GAD65 autoimmunity overlaps with autoimmune diabetes, but no effect on SPS mechanisms is shown |
| 3 | Opsismodysplasia | 98.59% | No plausible link; a genetic skeletal dysplasia (INPPL1/SHIP2) |
| 4 | Thiamine-responsive dysfunction syndrome | 98.58% | No direct link; the shared diabetes feature likely drives the association |
| 5 | Drug-induced localized lipodystrophy | 97.66% | Weak; fat-loss effects are conceptually opposite, and injection-site reactions are a concern |
| 6 | Centrifugal lipodystrophy | 97.56% | No established link; may be counterproductive |
| 7 | Pressure-induced localized lipoatrophy | 97.49% | No rationale; treatment is removing the pressure source |
| 8 | Idiopathic localized lipodystrophy | 97.35% | No established link; weight loss could be unfavourable |
| 9 | Pancreatic agenesis | 97.31% | Biologically implausible; efficacy depends on functioning beta cells. Only preclinical or safety literature was retrieved |
| 10 | Autoimmune oophoritis | 95.05% | Speculative; anti-inflammatory effects are reported, but no specific evidence |
Singapore Market Information
There are 15 valid single-ingredient registrations. The records compiled for this report include no approved indication text. Main authorizations:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16164P | OZEMPIC 1MG/DOSE Solution for Injection in Pre-filled Pen | Injection, solution | Not available |
| SIN16165P | OZEMPIC 0.25MG, 0.5MG/DOSE Solution for Injection in Pre-filled Pen | Injection, solution | Not available |
| SIN16215P | RYBELSUS Tablet 3mg | Tablet | Not available |
| SIN16216P | RYBELSUS Tablet 7mg | Tablet | Not available |
| SIN16706P | WEGOVY Solution for Injection in Pre-filled Pen 0.25MG/0.5ML | Injection, solution | Not available |
The remaining registrations are additional RYBELSUS (14 mg) and WEGOVY strengths. Available routes are injectable and oral.
Safety Considerations
- Drug Interactions: Interaction screening returned 100 records, of which 20 are listed in the data compiled for this report. Most are Moderate and a few are Minor. Examples include:
- Moderate: phenylephrine, pseudoephedrine, epinephrine, salbutamol, formoterol, hydrocortisone, triamcinolone, hydrochlorothiazide, acetazolamide, estradiol, ethinylestradiol, levonorgestrel, norethisterone, aripiprazole, asenapine, alpelisib, asparaginase and ethanol.
- Minor: topical hydrocortisone and topical alclometasone.
Package insert warnings and contraindications were not available. Please refer to the package insert for further safety information.
For the lipodystrophy-type predictions, semaglutide's fat- and weight-reducing effects and subcutaneous injection could add safety concerns rather than benefit.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a graph-based score alone, with no clinical trials, no supporting literature and no plausible mechanistic link. Semaglutide's GLP-1 receptor action has no known role in the GABAergic or autoimmune mechanisms of focal stiff limb syndrome.
To proceed, the following is needed:
- Mechanism of action data and a credible biological hypothesis linking GLP-1 receptor agonism to stiff-person spectrum disorders
- Preclinical or clinical evidence in focal stiff limb syndrome or stiff person syndrome
- Package insert warnings and contraindications from the HSA website, which is required for safety screening
- Route compatibility assessment, since this is still pending
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.